Candel's CAN-2409 Shows Promising Phase III Results, Boosts Stock Despite Challenges

Candel Therapeutics has announced that its investigational therapy, CAN-2409, successfully achieved the primary endpoint in its Phase III trial involving 745 patients with intermediate-to-high-risk localized prostate cancer[1][2]. This trial demonstrated a statistically significant 14.5% improvement in disease-free survival when CAN-2409 was administered alongside valacyclovir and standard radiation therapy[1]. Although the primary endpoint is non-traditional, Candel is bolstered by a Special Protocol Assessment with the FDA, potentially paving the way for a regulatory application and prospective approval by 2026[1][2].